Clinical trials: Glioblastoma
Glioma Glioblastoma Multiforme, Glioma, High Grade
PET-Guided Resection in High-Grade Gliomas
Background: Glioblastoma (GBM) is the most common primary brain tumor in adults, with a poor prognosis despite maximal treatment.
- Conditions
- Glioma Glioblastoma Multiforme, Glioma, High Grade, Glioma Surgery, Positron-Emission Tomography(PET)
- Trial name
- ResPGlioma (NCT07567196)
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Universita degli Studi di Genova
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
This phase II trial is studying how well vorinostat works in treating patients with progressive or recurrent glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00238303
- Testing
- vorinostat, conventional surgery
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma (GBM)
Safety and Efficacy of NRG-103 Injection in the Treatment of Recurrent Glioblastoma Patients
The goal of this clinical trial is to learn if NRG103 works to treat recurrent GBM in adults. It will also learn about the safety of NRG103.
- Trial name
- NCT06757153
- Testing
- NRG-103
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Zhongnan Hospital
Malignant Glioma of Brain
Panitumumab and Irinotecan for Malignant Gliomas
This is a phase II study of the combination of panitumumab with irinotecan in malignant glioma patients. The primary objective of the study is to determine the activity of the combination of panitumumab with irinotecan as…
- Trial name
- NCT01017653
- Testing
- Irinotecan, Panitumumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Annick Desjardins
Brain and Central Nervous System Tumors
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
RATIONALE: Thalidomide and celecoxib may stop the growth of tumor cells by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00047281
- Testing
- celecoxib, cyclophosphamide, etoposide
- Where
- 3 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Colorectal Cancer, Triple Negative Breast Cancer
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
The purpose of this trial is to evaluate changes in immune activity relative to baseline following treatment with Toca 511 and Toca FC in patients with solid tumors (including recurrent high grade glioma [rHGG]) or lymphoma.
- Conditions
- Colorectal Cancer, Triple Negative Breast Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT02576665
- Testing
- Toca 511, Toca FC
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Tocagen Inc.
Brain and Central Nervous System Tumors
Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00006353
- Testing
- temozolomide, radiation therapy
- Where
- 16 sites in Canada
- Volunteers
- 575 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Neoplastic Disease, Glioblastoma
Study of TLX101-Tx Plus Standard of Care (SoC) Versus SoC Alone for the Treatment of Patients With Recurrent Glioblastoma
This global clinical trial which evaluates the efficacy and safety of TLX101-Tx, an investigational radiopharmaceutical therapy, in combination with lomustine versus lomustine alone in adult patients with first recurrence of…
- Conditions
- Neoplastic Disease, Glioblastoma, Glioblastoma (GBM), Glioblastoma Multiform
- Trial name
- IPAX BrIGHT (NCT07100730)
- Testing
- TLX-101-Tx + Lomustine, TLX101-Tx
- Where
- 9 sites in Australia, Austria and 2 more
- Volunteers
- 50 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Caregiver, Glioblastoma Multiform (Grade IV Astrocytoma)
A Supportive Group Intervention for Caregivers to Patients Diagnosed With a Glioblastoma
Feasibility test and evaluation of a group intervention for caregivers to patients diagnosed with a glioblastoma.
- Trial name
- SUGRI (NCT06869577)
- Testing
- Project SUGRI: A supportive group intervention for caregivers to patients with a glioblastoma
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Glioma, Glioblastoma
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
Background: Gliomas are the most common malignant brain tumors. Some have certain changes (mutations) in the genes isocitrate dehydrogenase 1 (IDH1) or isocitrate dehydrogenase 2 (IDH2).
- Conditions
- Glioma, Glioblastoma, High Grade Glioma, Low Grade Glioma
- Trial name
- NCT03718767
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma
Glioblastoma Imaging Using a Strong Iron-like Bloodpool Contrast Medium?
Rationale: Visualization of tumor spread is of crucial importance when treating patients suffering from glioblastoma (GBM) as the success of tumor resection depends strongly on the extent of tumor infiltration.
- Trial name
- NCT05656300
- Testing
- MRI scan using USPIO particles
- Volunteers
- 15 people
- Sponsor
- Radboud University Medical Center
High Grade Glioma
Tumor DNA and MRI/CT Scan Findings in Patients With Grade III or Grade IV Malignant Glioma
RATIONALE: Studying levels of tumor DNA in the samples of blood from patients with cancer may help doctors find out whether the cancer has grown and how much.
- Trial name
- NCT00897611
- Testing
- DNA methylation analysis, polymerase chain reaction, computed tomography
- Volunteers
- 42 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma
The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections
The study is designed as an international, multicenter prospective cohort study. Patients with presumed glioblastoma (GBM) in- or near eloquent areas on diagnostic MRI will be selected by neurosurgeons.
- Trial name
- PROGRAM (NCT04708171)
- Testing
- Awake mapping under local anesthesia, Asleep mapping under general anesthesia, Resection under general anesthesia without mapping
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 453 people
- Sponsor
- Erasmus Medical Center
Glioblastoma, Brain Tumor
A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma
The main purpose of this study is to find out the highest possible dose of maprotiline that can be given safely in combination with temozolomide and tamoxifen.
- Trial name
- NCT04200066
- Testing
- Temozolomide, Tamoxifen, Maprotiline
- Sponsor
- University of Rochester
Brain and Central Nervous System Tumors
Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00028795
- Testing
- temozolomide, adjuvant therapy, radiation therapy
- Where
- 230 sites in United States, Australia and 5 more
- Volunteers
- 170 people
- Sponsor
- Children's Oncology Group
Glioblastoma
Retrospective Evaluation of Melanocortin Receptor 4 Polymorphisms in Patients With GBM Treated With Radiochemotherapy
Glioblastoma (GBM) accounts for approximately 50% of all glioma and among these tumors, are the most malignant. The cells of origin of glioma are still undefined, but the most putative target cells include astrocytes, neural stem…
- Trial name
- GLIOMELA (NCT02458508)
- Where
- Italy
- Volunteers
- 65 people
- Sponsor
- University of Pisa
Glioblastoma Multiforme
A Dose-finding Study of Birabresib (MK-8628) in Participants With Recurrent Glioblastoma Multiforme (MK-8628-002)
A study of single-agent birabresib (MK-8628) (formerly known as OTX015) in recurrent GBM after standard front-line therapy failure. The first phase of the study (dose escalation) will determine the maximum tolerated dose (MTD).
- Trial name
- NCT02296476
- Testing
- Birabresib
- Volunteers
- 12 people
- Sponsor
- Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Recurrent Glioblastoma
A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
The purpose of the study is to compare the efficacy and safety of nivolumab administered alone versus bevacizumab in patients diagnosed with recurrent glioblastoma (a type of brain cancer, also known as GBM), and to evaluate the…
- Trial name
- CheckMate 143 (NCT02017717)
- Testing
- Nivolumab, Bevacizumab, Ipilimumab
- Where
- 112 sites in United States, Australia and 10 more
- Volunteers
- 529 people
- Sponsor
- Bristol-Myers Squibb
Brain and Central Nervous System Tumors
Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for some types of brain tumors.
- Trial name
- NCT00004017
- Testing
- conventional surgery, iodine I 131 monoclonal antibody TNT-1/B
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Peregrine Pharmaceuticals
Glioma, Astrocytoma
Ga-68 Prostate Specific Membrane Antigen PET/CT in Gliomas
As a part of molecular imaging, many PET tracers have been investigated in this regard. Those include 18F-FDG being glucose analogue, 18F-FLT representing nucleoside metabolism, and 18F-FDOPA, 18F-FET, 11C-MET as amino acids…
- Conditions
- Glioma, Astrocytoma, Anaplastic Astrocytoma, Oligodendroglioma
- Trial name
- NCT06241391
- Testing
- PSMA PET-CT
- Where
- India
- Volunteers
- 35 people
- Sponsor
- All India Institute of Medical Sciences, Bhubaneswar